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ABSTRACT

Previously, Ara-A has been found to be an effective
antiviral agent against DNA virus infections.

In this

study, antiviral activity was shown against an RNA
virus, vesicular stomatitis virus.

The inhibitory

effect of Ara-A was found to occur early during virus
replication.

Cycloheximide, puromycin, and radioisotope

incorporation experiments showed that Ara-A seems to
stimulate protein synthesis while depressing RNA
synthesis.

The exact mode of action of Ara-A remains

unclear, however

some speculation concerning this

problem is reported herein.
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INTRODUCTION

Although Lee et; al. (i9 6 0 ) first synthesized
9-jJ-D-arabinofuranosyl adenine (Ara-A) with the
objective of evaluating its effectiveness as an
anticancer drug, subsequent studies have shown this
drug to be a potentially useful antiviral.

Privat de

Garilhe and de Rudder (1964) found that Ara-A inhibited
the production of infectious herpes simplex and vaccinia
viruses in cell culture.

The antiviral activity of

Ara-A in vitro against vaccinia virus was confirmed
by Freeman et al. (1 9 6 5 ).

Studies by Sidwell and

co-workers (1 9 6 7 ,1 9 6 8 ) extended the range of antiviral
activity of Ara-A in cell culture to include the
cytomegaloviruses as well as experimental vaccinia
virus infections in mice.
The expense of synthesis of Ara-A prevented
extensive experimentation (Cohen, 1 9 6 6 ) until this
compound was isolated from a Streptomvces antibioticus
(NRRL 3 2 3 8 ) fermentation by Parke, Davis and Co. (1 9 6 8 ).
Thereafter, in vivo experimentation for evaluating the
therapeutic effect of Ara-A was possible. Therapeutic
activity of Ara-A against experimental keratitis
(Sidwell et al., 1 9 6 9 ) and encephalitis (Schardein

1
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and Sidwell, 1 9 6 9 ) infections induced with herpes
simplex virus in hamsters has been demonstrated.
Sloan et al. (1 9 6 9 ) employed a wide range of
dose levels and routes of administration of Ara-A
in mice infected intracerebrally with herpes simplex and
observed that Ara-A was highly therapeutic and only
slightly toxic regardless of the route of administration
of the drug.
Miller et al. (1 9 6 9 ) have carried out extensive
screening of Ara-A against numerous DNA and RNA
viruses in vitro.

Their findings indicated the

restriction of Ara-A inhibition to DNA virus infections.
The only exception to their observations has been
the controversial inhibition of Rous sarcoma virus
specific foci.

Freeman et al. (1 9 6 5 ) reported no

inhibition of Rous sarcoma virus, whereas Miller et. al.
(1 9 6 9 ) found Rous sarcoma foci to be inhibited by Ara-A.
Inhibition of Rous sarcoma virus by Ara-A might be
explained on the basis of the DNA requirement of this
virus during replication (Bader, 1964,1966abj Temin,

1964).
The present study was undertaken as a result of
the finding that Ara-A inhibits the production of
infectious vesicular stomatitis virus (an RNA virus)

R eproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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grown in bovine kidney cell cultures.
Vesicular stomatitis virus (VSV) is a complex
bullet-shaped virus about 68 x 175 nm in size
(Howatson and Whitmore, 1962) which causes a serious
disease in cattle and lacks a DNA requirement during
its replicative cycle in vitro (Chamsey et al., 1963
and Prevec et al., 1 9 6 3 )*

Bradish and Kirkham (1 9 6 6 )

have described the ultrastructure of VSV as consisting
of four parts? a fringe of surface elements, a dense
limiting envelope, an helical shell of capsomeres, and
core material, with or without an axial hollow.

In

addition, they found that VSV generally exists in
two states; bullet-shaped infectious particles (B)
and truncated non-infectious (T) forms.
The nucleic acid core of VSV was found to be
single stranded RNA having a molecular weight of
3 x 10^ daltons (Brown et al., 1 9 6 7 ).

Subsequent

studies by Nakai and Howatson (1 9 6 8 ) showed that
the intact virion core existed as a ribbon-like strand
of a series of regular rod-like subunits having an
overall helical configuration.
Recently, Stampfer et al. (1 9 6 9 ) demonstrated
the complexity of VSV replication by isolating at
least nine different species of virus-specific RNA

R eproduced with permission of the copyright owner. Further reproduction prohibited without permission.

from infected cell cultures.

Of these species#

some were double stranded# some partially double
stranded and some single stranded.

When intact B

and T particles were compared# it was found that
B particles contained single stranded RNA sedimenting
at *K)S while T particles carried single stranded RNA
sedimenting at 19S.

Furthermore, Baltimore et al.

(1970) have shown that VSV carries an RNA polymerase
in the intact virion which is capable of synthesizing
messenger RNA directly from the intact nucleocapsid
as template without removal of protein (Baltimore,
1970).
Evidence presented here suggests a unique mode
of action of Ara-A against an RNA virus (VSV) which
appears to lack a DNA requirement during replication
in a cell line more closely related to the natural
host of the virus than those commonly employed by
other workers.
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MATERIALS AND METHODS

CELLS AND MEDIA
The MDBK bovine kidney cell line (Madin and
Darby, 195$) used

in these experiments was purchased

from Baltimore Biological Laboratory, Baltimore,
Maryland,

Monolayer cultures were grown and maintained

in medium ELay-10 FCS as previously described (Sabina
and Parker, 1963),

For experimental purposes, Eagle's

minimum essential medium (MEM) (Eagle, 1959) was
employed.

All culture media were sterilized by

passage through 0.2u porosity Cox filter membranes.

VIRUS
The Indiana serotype of vesicular stomatitis
virus (VSV) used in this study was supplied by Dr. N.A.
Labzoffsky, Ontario Department of Health, Toronto,
Ontario.

Stock virus was prepared by infecting MDBK

monolayers with an exposure multiplicity of ca. 2
plaque forming units (p.f.u.) per cell.

After adsorption

for 1 hour at 37°C, medium ELay-10 FCS was added and
cultures reincubated.

At 2k hours postinfection,

when the cytopathic effect was complete, all samples
were subjected to three cycles of freezing and thawing

R eproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to release intracellular infectious virus.

These

suspensions were then centrifuged at 2000 r.p.m. for
20 minutes in a Sorvall SS-3^ angle head rotor.

The

resulting infectious supernates were pooled and stored
at -60°C.

Titers of virus stocks ranged from

2.9 x 10^ to 7 . 5 x 10? p.f.u./ml.

INFECTION OF CELLS
MDBK monolayers grown in 1 oz. Brockway bottles
were generally used after 48 hours incubation at 37°C.
The medium was poured off and virus added at an
infecting multiplicity of ca. 15 unless otherwise
stated.

Adsorption was allowed to proceed for 1 hour

at 37°C with occasional agitation.

Thereafter,

residual virus innoculum was removed and the cultures
rinsed with Hank's Balanced Salt Solution (HBSS) prior
to the addition of medium MEM or MEM containing test
compounds.
Control cell monolayers were handled in a similar
fashion but received only MEM in place of virus
innoculum.

Unless otherwise indicated, all experiments

were carried out once using duplicate cultures and held
at -6o°C until assayed for infectivity or radioactivity.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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VIRUS ASSAY
Infectivity was estimated by plaque formation
in MDBK cell monolayers grown in 60-mm plastic tissue
culture dishes (Falcon Plastics, Los Angeles, California).
Replicate harvests of infectious virus from infected
cultures were obtained in a similar fashion to that
described under VIRUS.

Log dilutions of the samples

were made in medium MEM and 0.2 ml aliquots of
appropriate dilutions were added to duplicate MDBK
monolayers.

After 1 hour at 37°C

the cultures were

overlaid with 5 nil of agar medium (Sabina and Munro,
1969).

All dishes were then incubated at 3?°C in a

water saturated atmosphere of 5$ C02 in air.

The plaques

were counted after approximately 2k hours.

ISOTOPES AND INHIBITORS
■^H-L-valine (specific activity, 1.5 Ci/mM),
-^H-L-leucine (specific activity, 1 Ci/mM) and ^H-uridine
(specific activity, 5*0 Ci/mM) were purchased from
Amersham/Searle, Des Plaines, Illinois; cycloheximide
(Acti-Dione) and puromycin dihydrochloride from
Nutritional Biochemical Corp., Cleveland, Ohio; and
actinomycin D from Sigma Chemical Co., St. Louis,
Missouri.

The 9-j3-D-arabinofuranosyl adenine (micronized)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

8

was made available by Dr. R. Brackett, Parke,
Davis and Co., Detroit, Michigan.
Stock solutions of all chemicals were made in
MEM just prior to use, except actinomycin D and Ara-A
which were initially solubilized in ethanol and
dimethyl sulphoxide (DMSO), respectively.

RADIOISOTOPE INCORPORATION STUDIES
VSV-infected monolayers were prepared as described
under INFECTION OF CELLS.

Radioactive precursors were

added to monolayers at various times after infection
for 0.5 or 1 hour pulses.

Incorporation of

radioisotopes into cells was stopped by pouring off
the medium and washing twice with ice-cold HBSS.
Cold 0 . 5 N perchloric acid (PCA) was added to the
washed monolayers for storage at -20°C until extraction
procedures for RNA or protein were carried out.
Uninfected cultures were treated similarly.

EXTRACTION AND DETERMINATION OF PROTEIN AND RNA
The extraction procedure for protein and RNA was
carried out as follows.

Frozen cell monolayers which

had been exposed to radioactive precursors were thawed
at room temperature and the acid-precipitated cells

R eproduced with permission o f the copyright owner. Further reproduction prohibited without permission.
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scraped from the glass.

Cell suspensions were

transferred to centrifuge tubes and each culture
bottle rinsed with cold 0.5 N PCA.
were pooled and centrifuged.

Like suspensions

Each cell pellet was

washed once with cold 0 . 5 N PCA and dissolved in
0 . 5 N NaOH.

Separate aliquots of this solution were

taken for radioactivity and protein (Lowry et al., 1951)
determinations.
For RNA determinations, the alkaline samples were
incubated at 50°C for 20 minutes (Munro and Fleck,
1 9 6 6 ) and then reacidified to 0.5 N with respect to

perchloric acid.

After centrifugation, aliquants of

the acid soluble fractions were removed for radioactivity
and RNA (Merchant et al., i9 6 0 ) determinations.

RADIOACTIVITY ASSAY
Radioactivity was determined by the addition of
samples to scintillation fluid (Warner and McClean,
1 9 6 8 ).

Counts were obtained in a Nuclear Chicago

liquid scintillation counter, using either model
k6k3 or 6 8 5 0 .

Specific activities are reported

as counts per minute per milligram (c.p.m./mg) of
RNA or protein.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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RESULTS

MULTIPLICATION OF VSV
In order to establish the time-course of
VSV replication in MDBK cell monolayers, replicate
infected cultures were removed at various times after
infection and subsequently assayed for infectious virus.
Figure 1 illustrates the rapid replication of VSV
which reaches a maximum yield at about 16 hours
postinfection.

The latent phase is short and the

duration of the logarithmic growth phase is about 6
hours.

EFFECT OF ARA-A ON UNINFECTED MDBK CELLS
The effect of Ara-A on the survival of MDBK cells
was determined by setting up a series of cultures with
different concentrations of the drug in medium MEM.
Following Zk hours of incubation at 37°C, cultures were
checked for gross cytotoxicity at a magnification of
400x using a Leitz inverted microscope.

There was no

evidence of cytotoxicity in cultures exposed to Ara-A
in the range of 50 to 150 ug/ml when compared to
untreated control cultures.

However, in cultures 1

exposed to 200 ug of Ara-A/ml, extensive rounding of

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig. 1. Multiplication of vesicular stomatitis
virus in MDBK cells.

Duplicate infected cultures

were sampled at the indicated times.

Infectious

virus yields are expressed as plaque forming
units (p.f.u.)/ml.
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cells and some free floating cells were observed.

EFFECT OF DMSO ON MDBK CELLS
Since DMSO has been shown to be deleterious to
certain cell lines and viruses (Chang and Simon, 1 9 6 8 ),
it was important to establish its effect on MDBK cells
and VSV replication.

Replicate uninfected and VSV

infected MDBK monolayers were exposed to varying
concentrations of DMSO and allowed to incubate at
o
37 C until 2k hours postinfection.

Similar cultures

were observed in the absence of DMSO.
Microscopic examination of uninfected cultures
with and without DMSO gave very similar appearances
on the basis of gross morphology at a magnification
of kOOx,

The titers of infected cultures are shown

in Table 1 .

It appears that the highest concentration

of DMSO tested (0,6%) did not result in any decrease
in virus titer.

The final concentration of DMSO used

in the following experiments never exceeded 0,6%,

EFFECT OF ARA-A ON VSV INFECTIVITY
To evaluate the antiviral activity of Ara-A against
VSV, the drug was applied to replicate infected cultures
at levels of 5 0 , 100 and 150 ug/ml.

After 2k hours

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 1.

The effect of different concentrations of DMSO on
final infectious yields of VSV grown in MDBK cells.*

Concentration of DMSO (%)

*

Viral Yields (p.f.u./ml)

0

2.2 x 106

0.2

2.0 x 106

0.6

3.0 x io6

Indicated DMSO concentrations were added after

virus adsorption and samples titrated at 24 hours
postinfection.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of incubation at 37°C, infectious titers were determined
and per cent

plaque reduction values calculated.

It can be seen (Figure 2) that per cent plaque
reduction rises almost geometrically as the concentration
of Ara-A increases, indicating a typical dose-response
relationship.

All further studies in the presence

of Ara-A were carried out at a final drug concentration
of 150 ug/ml.

EFFECT OF MULTIPLICITY OF INFECTION ON VIRAL YIELDS
AND ARA-A INHIBITION
Because multiplicity of infection has been shown
to affect final yields of infectious virus (Stampfer
et al., 1 9 6 9 )* an experiment was carried out to
establish the optimal multiplicity of infection in
this test system.
Table 2 shows that maximal yields of VSV in the
absence of Ara-A were obtained at a multiplicity of
$.0.

However, the inclusion of Ara-A resulted in a

bicyclic pattern of inhibition.

In order to evaluate

the antiviral activity of Ara-A, it was pertinent to
have the entire cell population infected, therefore,
all subsequent experiments were begun with an infecting
multiplicity of ca. 15*

R eproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig. 2.

The effect of different concentrations

of Ara-A on final yields of infectious VSV.
Cultures were exposed to different concentrations of
Ara-A as indicated after adsorption.
were incubated in MEM.

Control cultures

Samples were titrated at Zk

hours postinfection and per cent inhibition values
calculated.

Fig. 2 presents average per cent inhibition

values from two experiments.
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Table 2.

The effect of multiplicity of infection on viral
yields and Ara-A inhibition.*

Multiplicity of

Virus Yield (p.f .u../ml)

infection (p.f.u./cell)
MEM

*

MEM + Ara-A

0.01

5.7 x 1 0 ^

1.0 X 105

0.1

4.0 x 106

6.0 X 105

1.0

5.2 x 106

3.8 X 106

3.4

4.4 x 106

1.7 X 106

5.0

8.? x 106

2.2 X 106

1 5 .0

8.7 x 106

1.0 X 106

Duplicate cultures were exposed to the indicated

infecting multiplicities.

Ara-A (150 ug/ml), when

present, was added after adsorption.

Virus yields

were determined at 24 hours postinfection.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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MULTIPLICATION OF VSV IN THE PRESENCE OF ARA-A
To obtain information about the inhibitory effect
of Ara-A upon VSV replication in MDBK cells, an
experiment was performed similar to that described
for the infectivity curve of VSV except that Ara-A
was incorporated into medium MEM.

The experimental

results are shown in Figure 3«
Comparison of the infectivity curves of untreated
cultures (Figure l) and Ara-A treated cultures (Figure 3)
showed that Ara-A caused a rapid drop in virus yield
beginning about 9 hours postinfection.

With untreated

cultures, the exponential rate of virus multiplication
was extended until maximal steady levels were reached
after 12 hours of infection.

ADDITION OF ARA-A TO INFECTED CELLS
Further definition of the period of Ara-A activity
in MDBK infected cultures was studied by adding the
drug at different intervals after infection for varying
periods of time.

Control infected cultures were allowed

to incubate in medium MEM for the 24 hour test period.
Infectious titers of the samples were determined and
expressed as the per cent of the 2k hottr control
culture (Figure k ).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Pig. b,

Effect on infectious yields of pulsing MDBK

cells with Ara-A.

Ara-A (150 ug/ral) was added to

duplicate cultures for the indicated time periods.
Control infected cultures were incubated in MEM.
All samples were allowed to incubate for 2b hours.
When MEM containing Ara-A was removed, the cultures
involved were washed twice with HBSS prior to the
addition of MEM alone for reincubation.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig. 3»
of Ara-A.

Multiplication of VSV in the presence

Legend as for Fig, 1 except that Ara-A

(150 ug/ml) was added to all cultures at the time of
infection.
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The addition of Ara-A during the first 3 hours
of infection resulted in about 70# inhibition whereas
only a slight increase in inhibitory activity was
evident when the drug was present from 6 to 2k hours
postinfection.

It is also clear that the presence of

Ara-A during the first hour of infection did not
effectively inhibit virus development.

These effects

suggest that Ara-A is most active early during viral
replication but after the first hour of infection.

ADDITION OF PUROMYCIN AND ARA-A TO INFECTED CELLS
To determine whether Ara-A inhibition was dependent
on protein synthesis, puromycin at a final concentration
of 20 ug/ml was added to infected monolayers
in combination with and without Ara-A.

Virus-infected

control cultures were incubated in medium MEM.
As shown in Figure 5» when puromycin was used
for the first 3 hours after infection, the presence
of puromycin and Ara-A showed less inhibition than
did puromycin alone.

During the 6 to 2k hour and

0 to 2k hour periods, differences were relatively
small.

Apparently, Ara-A relieves puromycin inhibition

rather than acting synergistically.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig. 5»

^he effect on infectious yields of pulsing

monolayers with puromycin (20 ug/ml) and puromycin
(20 ug/ml) plus Ara-A (150 ug/ml) for the indicated
time periods.
Fig. 4,
alone.

Conditions were similar to those for

Solid bars indicate the effect of puromycin
Cross-hatched bars indicate the effect of

puromycin plus Ara-A.
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ADDITION OF CYCLOHEXIMIDE AND ARA-A TO INFECTED CELLS
To ascertain the influence of a different protein
inhibitor in combination with Ara-A on VSV-infected
cells, cycloheximide at a level of 20 ug/ml was tested
as described in the preceding experiment.

Since

cycloheximide is reported to act by binding only to
eukaryotic ribosomes (Brock, 1970), it was expected
that only cellular protein synthesis would be affected
in this experiment.
Figure 6.

The results are illustrated in

The difference in inhibition induced by

cycloheximide and puromycin was found to be only
10 to 15%•

Also, the addition of combined cycloheximide

and Ara-A was considerably less inhibitory to virus
production than cycloheximide alone.

INCORPORATION OF 3H-L-VALINE INTO INFECTED AND
UNINFECTED CELLS WITH AND WITHOUT ARA-A
Since Ara-A had been shown to relieve inhibition
of VSV replication by the protein inhibitors tested,
it was of interest to discover whether Ara-A stimulated
protein synthesis.

Replicate cultures were pulsed

for 1 hour at various times after infection with
3H-L-valine as described under RADIOISOTOPE INCORPORATION
STUDIES.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig. 6.

The effects of cycloheximide and

cycloheximide plus Ara-A on VSV infectious yields.
Legend as for Fig. 5 except cycloheximide (20 ug/ml)
was substituted for puromycin.
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Figure 7A showed that Ara-A had a slight depressing
effect on ^H-valine incorporation into uninfected
cultures.

With virus-infected cultures (Figure ?B),

the rate of incorporation of ^H-valine into both
Ara-A treated and untreated cultures was found to be
gradually inhibited throughout the 10-hour test period.
The magnitude of inhibition varied since cultures
exposed to Ara-A up until 5 hours postinfection showed
somewhat more radioactivity than untreated cultures
at this time.

Prolonged treatment with Ara-A caused

similar inhibition of radioactivity incorporation
compared to untreated cultures.

INCORPORATION OF 3H-L-LEUCINE IN THE PRESENCE OF
ACTINOMYCIN D INTO INFECTED AND UNINFECTED CELLS
WITH AND WITHOUT ARA-A
In order to preclude masking of viral events by
normal cellular protein synthesis, actinomycin D at
a final concentration of 3 ug/ml was added to all
cultures.

In these experiments, duplicate infected

cultures were exposed to ^H-L-leucine for 0.5 hour
pulses beginning at various times after infection.
When Ara-A was present, the drug was added at the time
of infection.
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Pig. 7.

^H-L-valine incorporation into

uninfected (A) and infected (B) cells in the presence
and absence of Ara-A.
with ^H-L-valine

General conditions for pulsing

uCi/culture), harvesting,

extraction and counting procedures were described
in MATERIALS AND METHODS.

Ara-A (150 ug/ml) when

used, was applied at the time of infection.

Solid

bars indicate the absence of Ara-A, cross-hatched
bars its presence.
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The radioactivity incorporation profiles of
uninfected cultures containing actinomycin D without
and with Ara-A were essentially the same (Figure 8).
When similarly treated infected cultures were compared,
there was a greater rate of incorporation in Ara-A
treated samples except during the 0,5 to 1 hour
pulse (Figure 9)«

Although infected cultures with

Ara-A incorporated ^H-leucine at a greater rate, the
pattern of incorporation was comparable to infected
controls.

Compared to the ^H-valine experiment, the

general trend of incorporation of ^H-leucine after
infection in the presence of actinomycin D was upward.
This finding is consistent with the synthesis of viral
directed proteins.

INCORPORATION OF 3H-URIDINE IN THE PRESENCE OF
ACTINOMYCIN D INTO INFECTED AND UNINFECTED CELLS
WITH AND WITHOUT ARA-A
It was necessary to observe the influence of
Ara-A on viral RNA synthesis during VSV replication.
Therefore, an experiment similar to the preceding one
3
was carried out using H-uridine. When specific
activities for uninfected cultures were obtained
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Fig. 8.

^H-L-leucine incorporation in the

presence of actinomycin D into uninfected cultures
without and with Ara-A.

General conditions were as

described for Fig. 7 except %-L-leucine (6 uCi/culture)
was substituted for ^H-L-valine and actinomycin D
(3 ug/ml) was present in all cultures.
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Fig. 9.

^H-L-leucine incorporation in the

presence of actinomycin D into infected cells without
and with Ara-A.

Legend as for Fig. 8 except infected

cultures were used.
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Fig. 10.

%-uridine incorporation in the

presence of actinomycin D into uninfected cells
with and without Ara-A.

Legend as for Fig. 8 except

-^H-uridine (3 uCi/culture) was used.

Solid bars

indicate the absence of Ara-A, cross-hatched bars
its presence.
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(Figure 1 0 ), there was little change in the amount
of incorporation of -^H-uridine throughout the
experiment compared to infected cultures.
In infected cultures (Figure 11), the presence
of Ara-A resulted in considerably lower amounts of
incorporation during the first two pulses with little
effect during the remaining pulses.

The overall trend

in the presence or absence of Ara-A showed a marked
drop in the incorporation of radioisotope with time.
Since actinomycin D had previously been shown not to
affect VSV replication (Huang and Wagner, 1966 s Black
and Brown, 1 9 6 8 ), these results were puzzling.

The

virus stock used in these experiments was checked
for infectivity in order to exclude inactivation as
a cause for such results.

The stock virus suspension

was found to be fully active.

Shortly after the

conclusion of these experiments, Yamazaki and Wagner
(1970) reported similar findings with VSV in rabbit
kidney cells.

Even under such adverse conditions as

described above, Ara-A still caused a reduced rate of
incorporation of -^H-uridine compared to the infected
control as early as the 0 .5 to 1 hour pulse.
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Fig. 11.

^H-uridine incorporation in the

presence of actinomycin D into infected cells with
and without Ara-A.

Legend as for Fig. 8 except

^H-uridine (3 uCi/culture) and infected cultures were
used.
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INCORPORATION OF 3 H-URIDINE INTO INFECTED AND UNINFECTED
CELLS WITH AND WITHOUT ARA-A
Since actinomycin D was found unsuitable to
study VSV RNA synthesis, the preceding experiment
was duplicated in full without the addition of
actinomycin D*
12 and 13.

These results are reported in Figures

The incorporation rates for uninfected

cultures (Figure 12) show little variation throughout
the course of the experiment.

Ara-A exhibited a slight

depressing effect on incorporation in uninfected
cultures.

Infected cultures (Figure 13) without Ara-A

demonstrated increased rates of incorporation of
%-uridine over control values during pulses beginning
at 0 .5 , 3 .5 , 5 .5 and ? hours after infection.
Comparison of Ara-A treated infected samples with
uninfected controls showed the greatest increase in
rate of incorporation during the first pulse.

Specific

activities for infected cultures with and without
Ara-A (Figure 13) show generally lower rates of
incorporation in the presence of Ara-A.

In addition,

the greatest differences were noted during the 0 .5 to 1
and 5 .5 to 6 hour pulses,where values for cultures
lacking Ara-A were considerably higher.
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Fig, 12,

^H-uridine incorporation into uninfected

cells with and without Ara-A.

Legend as for Fig. 7

except ^H-uridine (3 uCi/culture) was substituted for
•^H-L-valine.
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Fig. 13.

3H-uridine incorporation into infected

cells with and without Ara-A.

Legend as for Fig. 7

except ^H-uridine (3 uCi/culture) and infected
cultures were used.
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DISCUSSION

Previously, studies of the antiviral activity of
Ara-A have shown high therapeutic activity against
DNA viruses but not against RNA viruses.

This study

reports the first incidence of Ara-A activity against
an RNA virus (VSV) other than Rous sarcoma virus
which has been shown to be dependent on DNA synthesis
for replication (Bader, 1964-, 1966 abj Temin, 1964-).
Ara-A antiviral activity against VSV has been demonstrated
to occur early during replication confirming the
findings of Miller et al. (1969) in connection with
DNA viruses.
Although Ara-A has been shown to be an effective
antiviral agent (Miller et al., 1 9 ^9 j Sidwell et al..
1967, 1 9 6 8 , 1 9 6 9 * Sloan et al., 1969) its exact mode
of action remains unknown.

On the basis of •'H-L-leucine

incorporation in the presence of actinomycin D, evidence
has been presented here indicating a lack of inhibition
of viral protein synthesis by the drug.

The relief

by Ara-A of puromycin and cycloheximide inhibition
of VSV infectivity may imply association of the drug
with ribosomes and/or transfer RNA.

This association,

if it exists, does not seem to inhibit protein synthesis
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but in fact appears to stimulate the incorporation of
%-L-leucine in the presence of actinomycin D. This
3
stimulation was apparently masked in the H-L-valine
incorporation experiment which probably reflects the
trend of cellular protein synthesis during VSV infection.
The decrease in incorporation of %-L-valine as VSV
infection progresses confirms recent findings by
Wertz and Younger (1970).
Early viral RNA synthesis is partially inhibited
by Ara-A as demonstrated by ^H-uridine incorporation
but does not seem extensive enough to account for the
inhibition of later viral RNA synthesis.

Baltimore

et a l . (1970) have shown that early viral RNA synthesis
in VSV-infected cells is directed by the intact
infecting nucleocapsid and may be carried out by an
RNA polymerase carried in the intact virion.
Furthermore, Baltimore (1970) has hypothesized that
early viral RNA formation and replication of the
viral genome are separate events.

Therefore, the

evidence presented here seems to indicate direct
inhibition of the replication of the viral genome.
Lucas-Lenard and Cohen (1 9 6 6 ) have reported that
the 5 ‘-diphosphate derivative of Ara-A (Ara-ADP)
inhibits the action of the enzyme polynucleotide
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phosphorylase isolated from Esoherichia coli.

This

enzyme (Edmonds and Abrams, I960; Ventkataraman and
Mahler, 1963) and one of its products, polyadenylic
acid (Poly A) (Hadjivassiliou and Brawerman, 1 9 6 6 ),
have been isolated from mammalian systems.

Ara-A

has also been shown to inhibit DNA synthesis in
TA 3 ascites cells (Brink and LePage, 1 9 6 6 ) and to
inhibit DNA polymerase in mammalian cells (Furth and
Cohen, 1 9 6 7 ).
Polynucleotide phosphorylase has been shown to
be capable of synthesizing RNA (Grunberg-Manago'and
Ochoa, 1955) and cellular RNA synthesis has been
shown to be shut off rapidly after VSV infection
(Huang and Wagner, 1965? Wertz and Younger, 1970).
Therefore, one might speculate that this enzyme is
similar to the RNA-dependent RNA polymerase carried
in the VSV virion.

Also, the comparatively little

inhibition of early viral RNA formation may be a
reflection of a protective effect due to complexing
of the enzyme with the nucleocapsid.
As yet, there have been no reports dealing with
radioisotope labelled Ara-A in viral infections.
In vitro studies of L cells by Cohen (1 9 6 6 ) failed
to show incorporation of tritium-labelled Ara-A into
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DNA, RNA or nucleotides.

York and LePage (19 6 6 )

found Ara-ATP inhibition of DNA polymerase in TA^
ascites cells to be non-competitive.

These findings

seem to indicate that Ara-A may inhibit VSV replication
by affecting the enzyme responsible for the replication
of the VSV genome although the drug does not seem to
bind to the active site of similar enzymes.
In conclusion, although the exact mode of action
of Ara-A against VSV remains to be determined, the
drug does not appear to be a protein synthesis inhibitor
but appears to block viral RNA synthesis in some manner.
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SUMMARY

Ara-A has been shown to be effective in inhibiting
the replication of vesicular stomatitis virus (VSV)
in MDBK cells as early as the first three hours of
infection.

Ara-A was shown to follow a typical dose-

response relationship in this test system.

When used

in combination with the protein synthesis inhibitors
puromycin and cycloheximide, Ara-A seems to relieve
inhibition of infectivity rather than acting
synergistically.

Radioisotope incorporation studies

showed that VSV infection shuts off protein synthesis
in MDBK cells and that Ara-A did not affect this
process.

When incorporation of ^H-L-leucine in the

presence of actinomycin D was studied, Ara-A was shown
to stimulate incorporation.

Incorporation experiments

utilizing %-uridine demonstrated inhibition of viral
RNA synthesis during the period of expected genome
replication.
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